SMMT - Summit Therapeutics plc

NasdaqGM - NasdaqGM Delayed Price. Currency in USD

Summit Therapeutics plc

136a Eastern Avenue
Milton Park
Abingdon OX14 4SB
United Kingdom
44 12 3544 3939

Full Time Employees40

Key Executives

Mr. Glyn O. Edwards MBEChief Exec. Officer and Exec. DirectorN/AN/A61
Mr. Erik OstrowskiChief Financial Officer1.13MN/A44
Prof. Kay Davies FRS CBECo-Founder, Chairman of Scientific Advisory Board and Scientific AdvisorN/AN/A67
Prof. David Roblin BSc, MBBS, FRCP, MFPMChief Operating Officer, Chief Medical Officer and Pres of R&DN/AN/A50
Ms. Michelle AveryDirector of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

Corporate Governance

Summit Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.